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At ﬁrst glance, obesity seems to be clearly associated with an
increased risk for cardiovascular (CV) events, CV death, and
even all-cause death. This has been proven in numerous
studies investigating this relationship in patients without
prior CV events (1). However, there is increasing evidence
that the association between body mass index (BMI) and
CV morbidity/mortality or all-cause mortality is reversed in
selected patient populations, in particular in patients with
previous CV events. This phenomenon has been named the
“obesity paradox.” In detail, the obesity paradox states that
under certain conditions such as chronic heart failure, an
elevated BMI positively correlates with improved prognosis
or decreased risk (2). Previously, the paradox has been only
described in regional cohorts. Furthermore, it appears that
the paradox may largely apply to distinct subgroups of pa-
tients; however, robust data for subgroup identiﬁcation are
still missing.
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In this issue of the Journal, Shah et al. (3) studied the
obesity paradox in 6,142 patients with acutely decompen-
sated heart failure from 12 prospective observational cohorts
across 4 continents. The analysis comprised patients with
acute decompensated heart failure including those with
new onset heart failure and those with acute cardiac decom-
pensation of chronic failure from 8 European studies, 2
North American studies, 1 Asian study, and 1 study from
South America. The population was stratiﬁed into 3 BMI
categories: normal weight (BMI: 18.5 to 25 kg/m2), over-
weight (BMI: 25 to 30 kg/m2), and obese (BMI:30 kg/m2),
and as the primary outcome, all-cause mortality was analyzed
at 30 days and 1 year of follow-up by medical chart review.
Baseline characteristic of the study population revealed
that normal weight patients were older, with more severe
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paper to disclose.and lower prescription rates of cardiovascular drugs such as
beta-blockers, blockers of the renin-angiotensin system,
and statins. The investigators applied a Cox proportional
hazards model and net reclassiﬁcation index to describe the
association between BMI and the primary outcome. In
consonance with recently published data, a higher BMI
was associated with a decreased 30-day mortality in an un-
adjusted model but not in the fully adjusted model, and
more importantly, long-term mortality (1 year) was reduced
in higher BMI categories using both statistical models.
These results conﬁrm the notion that in acute heart failure,
a higher BMI particularly improves long-term prognosis.
Worth mentioning is the regional heterogeneity of the study
population corroborating the existence of a global obesity
paradox. An even more important piece of data is presented
in the further analysis of the data focusing on subgroup
identiﬁcation. Shah et al. (3) report that a higher BMI is
associated with lower mortality particularly among older
patients more than 75 years of age, in patients with reduced
ejection fraction, in patients without diabetes, and in patients
with de novo acute heart failure on admission.
The identiﬁcation of selected subgroups in whom the
obesity paradox is particularly applicable provides an
important contribution to the controversially discussed ex-
istence of the paradox in heart failure (2,4). Looking at these
data one may conclude that both sides of the controversy are
justiﬁed. The obesity paradox does not apply to the general
population of patients with acute decompensated heart
failure. But looking through the glasses of an “individualized
medicine,” the paradox seems to exist for selected patients:
nondiabetic, older patients with reduced cardiac function
and de novo heart failure.
With respect to the present study, one of the most impor-
tant questions remains: Do these ﬁndings translate into
clinical or therapeutic practice? In the case of future conﬁr-
matory data, subgroup characterization should deﬁnitely
determine future individualized therapeutic approaches.With
a focus on acute/chronic heart failure, one should identify
patient subpopulations who beneﬁt from body weight
reduction, patients who beneﬁt from body weight mainte-
nance, and patients who beneﬁt from body weight gain or a
positive energy balance. Independent of the more “academic”
discussion about the existence of the obesity paradox, future
prospective interventional studies need to center around
practical solutions for an individualized body weight/energy
balance–guided supportive therapy for heart failure. The study
by Shah et al. (3) may act as a kick off.
One limitation of the present study that requires further
discussion comes from the more general question, whether
BMI alone is an adequate parameter to address the complex
interactions between obesity and CV risk? BMI has been used
in most of the published studies investigating the obesity
paradox. As previously pointed out by other investigators (5),
BMI includes multiple metabolic measures including fat
mass, lean or fat-free mass, water, and so forth, and seems
to be a rather inaccurate parameter. To do justice to the
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787complex metabolic processes involved in obesity-mediated
CV disease progression/regression, a more precise param-
eter/technique for body composition such as magnetic reso-
nance imaging or dual-energy X-ray absorptiometry should
be tested in future studies (6,7). In addition to the relevance
of body composition, cardiorespiratory ﬁtness has been
recently pointed out as a more relevant CV risk predictor
than BMI alone (8). Along this line, cardiorespiratory ﬁtness
has already been investigated as an additional important
determinant for the relationship between overweight/obesity
and CV risk in the context of the obesity paradox (5).
Taken together, it appears that a global individualized
obesity paradox exists. However, future prospective and even
interventional studies using advanced metabolic measures
are absolutely required to ﬁnally develop metabolically
guided supportive therapy for heart failure patients.
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